STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Citadel Affiliates Disclose 5.33M Shares in LXEO, Representing 9.6%

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Citadel-linked entities disclose a substantial passive stake in Lexeo Therapeutics (LXEO). Collectively, Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC report beneficial ownership of 5,325,269 shares, representing 9.6% of outstanding shares on a fully calculated basis of 55,718,516 shares (including 1,717,302 shares issuable upon warrant conversion). Citadel Securities entities separately report 8,843 shares. Kenneth Griffin is reported to beneficially own 5,334,112 shares (also 9.6%). The filing states the positions were not acquired to change or influence control and identifies the reporting persons, organization structure and shared voting/dispositive powers.

Positive

  • Material ownership disclosed: Citadel-affiliated entities report a clear 9.6% beneficial stake in LXEO, improving market transparency
  • Detailed ownership structure: Filing identifies specific entities, shared voting and dispositive powers, and inclusion of shares issuable upon warrant conversion
  • Passive intent certified: Reporting persons certify the holdings were not acquired to change or influence control, consistent with Schedule 13G treatment

Negative

  • None.

Insights

TL;DR: Citadel affiliates disclosed a sizable 9.6% passive stake in LXEO, a material ownership position that increases institutional concentration.

The Schedule 13G shows a nearly 10% position held collectively by Citadel-managed funds and related entities, using a 55.7 million share base that includes convertible warrants. For investors this raises institutional concentration and potential liquidity considerations; the filing characterizes the stake as passive under Section 13(g), which implies no intent to influence control. The precise share counts and shared voting/dispositive powers are disclosed, improving transparency around ownership structure.

TL;DR: A 9.6% disclosure is material for governance monitoring but the filer affirms passive intent under Schedule 13G.

The document identifies the reporting chain (portfolio manager, holding companies, GP entities, and Kenneth Griffin) and quantifies shared voting and dispositive power, which is important for directors and governance committees tracking influential holders. The explicit certification that shares were not acquired to change control reduces immediate takeover or activist signaling, though the position size warrants ongoing disclosure monitoring.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 55,718,516 Shares outstanding comprised of (i) 54,001,214 Shares outstanding as of June 2, 2025 (according to the issuer's registration statement on From S-3 as filed with the Securities and Exchange Commission on June 13, 2025), and (ii) 1,717,302 Shares issuable upon conversion of certain warrants held by affiliates of the reporting persons.


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Citadel Advisors LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2025
Citadel Advisors Holdings LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2025
Citadel GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2025
Citadel Securities LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2025
Citadel Securities Group LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2025
Citadel Securities GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:08/14/2025
Kenneth Griffin
Signature:/s/ Seth Levy
Name/Title:Seth Levy, attorney-in-fact*
Date:08/14/2025

Comments accompanying signature: * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.

FAQ

How many LXEO shares do Citadel entities report owning?

The filing reports Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC beneficially own 5,325,269 shares; Citadel Securities reports 8,843 shares.

What percentage of LXEO does the reported position represent?

The reported position represents 9.6% of LXEO's outstanding shares based on 55,718,516 shares used in the filing's calculation.

Does the filing indicate intent to influence control of Lexeo Therapeutics (LXEO)?

No. The certification states the securities were not acquired and are not held to change or influence control, consistent with a Schedule 13G passive filing.

Who among the Citadel reporting persons is individually identified as a beneficial owner?

Mr. Kenneth Griffin is identified and may be deemed to beneficially own 5,334,112 shares.

Does the ownership count include potential shares from warrant conversion?

Yes. The 55,718,516-share base includes 1,717,302 shares issuable upon conversion of certain warrants held by affiliates, per the filing.
Lexeo Therapeutics Inc

NASDAQ:LXEO

LXEO Rankings

LXEO Latest News

LXEO Latest SEC Filings

LXEO Stock Data

607.25M
68.04M
0.53%
89.37%
9.69%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK